Video

Dr. Tannir on CANTATA study of telaglenastat plus cabozantinib in mRCC

Author(s):

Urology Times staff
Conference|ASCO Annual Meeting: Bladder Cancer and RCC

Nizar M. Tannir, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.

Current Time 0:00
Duration 4:45
Loaded: 0%
Stream Type LIVE
Remaining Time 4:45
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Nizar M. Tannir, MD, MD Anderson Cancer Center, discusses results from the phase 2 CANTATA study of cabozantinib (Cabometyx) plus either the novel glutaminase inhibitor telaglenastat (CB-839) or placebo in patients with advanced/metastatic renal cell carcinoma who progressed on immune checkpoint inhibitors or antiangiogenic therapies.

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
    Jad Chahoud, MD, on the phase 1b STELLAR-002 trial in ccRCC
    Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
    Jens Bedke, MD, on efficacy of EV plus pembrolizumab across subgroups in la/mUC
    Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
    Professor Dickon Hayne shares data on mitomycin plus BCG in high-risk NMIBC
    Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
    Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
    Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
    Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
    Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
    Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
    Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
    Andrew Armstrong, MD, previews key prostate cancer data at ASCO 2025
    5 key trial insights from AUA 2025
    5 key trial insights from AUA 2025
    Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
    Shreyas Joshi, MD, recaps AUA session on chemotherapy vs novel NMIBC options
    Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
    Shay Rajavel, MS3, on CO2 gas embolism during single-port partial nephrectomy
    Related Content
    Second-line cabozantinib shows efficacy in advanced renal cell carcinoma
    June 9th 2025

    Second-line cabozantinib shows efficacy in advanced renal cell carcinoma

    Hannah Clarke
    The regimen showed activity regardless of the prior immunotherapy-based combination used in the first-line setting.
    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25
    May 4th 2025

    Pearls & Perspectives: Expanding BPH care & patient choice, with Kevin Zorn, MD, at AUA 25

    Amy M. Pearlman, MD Kevin C. Zorn, MD, FRCSC, FACS
    Urologists discuss innovative BPH treatments, emphasizing personalized care, and the importance of ejaculatory preservation.
    Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC
    June 5th 2025

    Data supports mitomycin plus BCG as alternative to BCG alone in NMIBC

    Hannah Clarke
    According to the authors, the mitomycin/BCG regimen could alleviate some of the burden of the global BCG shortage.
    Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025
    April 30th 2025

    Pearls & Perspectives: Future of reconstructive urology, with Ryan Terlecki, MD, at AUA 2025

    Amy M. Pearlman, MD Ryan Terlecki, MD
    A discussion on evolution of surgical education, importance of video training, and the future of patient-centered care in reconstruction.
    Amy L. Shaver, PhD, PharmD, MPH
    June 5th 2025

    GLP-1 agonist use is rising in men with prostate cancer

    Benjamin P. Saylor
    In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
    Adding niraparib to AAP extends rPFS in HRR-positive mCSPC
    June 4th 2025

    Adding niraparib to AAP extends rPFS in HRR-positive mCSPC

    Hannah Clarke
    “AMPLITUDE supports early genomic testing and niraparib plus AAP as a new treatment option for patients with mCSPC and HRR gene alterations," the authors wrote.
    © 2025 MJH Life Sciences

    All rights reserved.